Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs).
Latest news
16 Sep, 2020
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
27 May, 2020
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
Meet the team
Douglas Thomson
Chief Executive Officer
Dr David Howat
Development Director
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board